{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"43"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"23"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"63"}],"units":"Scans"}],"title":"T1-weighted post-contrast and fluid attenuated inversion recovery"},{"categories":[{"measurements":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"42"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"23"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"63"}],"units":"Scans"}],"title":"T1-weighted post-contrast and T2-weighted"},{"categories":[{"measurements":[{"groupId":"OG000","value":"66"},{"groupId":"OG001","value":"60"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"25"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"77"}],"units":"Scans"}],"title":"Fluid attenuated inversion recovery and T2-weighted"}],"denomUnitsSelected":"Scans","denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"25"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"77"}],"units":"Scans"}],"description":"Response categories (complete response, partial response, stable disease, and progression) will be determined from the following three standard magnetic resonance sequences, T2-weighted, fluid attenuated inversion recovery, T1-weighted post-contrast. Percent agreement between the sequences will be estimated as the number of follow-up scans in which the corresponding sequence agreed divided by the total number of follow-up scans.","groups":[{"description":"Patients receive low-dose lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.\n\nLenalidomide: Given PO\n\nPharmacological Study: Correlative studies","id":"OG000","title":"Arm I (Low-dose Lenalidomide)"},{"description":"Patients receive high-dose lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.\n\nLenalidomide: Given PO\n\nPharmacological Study: Correlative studies","id":"OG001","title":"Arm II (High-dose Lenalidomide)"}],"paramType":"NUMBER","populationDescription":"Scans completed and reviewed by standard magnetic resonance sequences. Only eligible patients are considered in the analysis of this outcome measure.","reportingStatus":"POSTED","timeFrame":"Up to 3 years","title":"Magnetic Resonance Imaging Sequence","type":"SECONDARY","typeUnitsAnalyzed":"Scans","unitOfMeasure":"Number of scans in agreement"}